首页|黄葵胶囊联合缬沙坦治疗糖尿病肾病临床疗效探讨

黄葵胶囊联合缬沙坦治疗糖尿病肾病临床疗效探讨

扫码查看
目的 研究分析黄葵胶囊联合缬沙坦治疗糖尿病肾病临床疗效.方法 选取2014年4月~2016年10月象山县中医医院所收治的50例糖尿病肾病患者作为本次研究过程中的研究对象,随机分为对照组和实验组2组,各25例.对照组患者进行缬沙坦治疗,实验组患者进行黄葵胶囊联合缬沙坦治疗,比较分析实验组与对照组患者的治疗效果以及总胆固醇以及尿白蛋白排泄率等指标.结果 进行治疗前,实验组与对照组患者甘油三酯、总胆固醇以及尿白蛋白排泄率等指标并无显著差异,没有统计学意义,能够进行比较.经过治疗后,实验组患者的尿蛋白排泄率以及胆固醇和甘油三酯水平显著低于对照组患者,差异具有统计学意义(P<0.05).对照组25例患者中,总有效例数为20例,有效率为80.0%.实验组25例患者中,总有效例数为24例,有效率为96.0%.对照组患者的治疗效果显著低于实验组患者,具有统计学差异(P<0.05).实验组与对照组糖尿病肾病患者中均未出现严重的并发症情况.结论 黄葵胶囊联合缬沙坦治疗糖尿病肾病能够在很大程度上提高治疗有效率,安全性较高,并无明显的不良反应,提高了患者的生活质量,最大程度上降低了患者的痛苦,具有临床进一步推广和应用的意义.
To explore the clinical curative effect of Huangkui capsule combined with valsartan in the treatment of diabetic nephropathy
Objective To study the clinical effect of Huangkui capsule combined with valsartan in the treatment of diabetic nephropathy.Methods50 patients with diabetic nephropathy treated in our hospital from April 2014 to October 2016 were selected as the research object in this study.They were randomly divided into the control group and the experimental group (n=two), with each group having a total of 25 patients.The control group was treated with valsartan treatment, patients in the experimental group of Huangkui capsule combined with valsartan treatment, comparative analysis of the experimental group and the control group of patients the treatment effect and total cholesterol and urinary albumin excretion rate.ResultsBefore treatment, there was no significant difference between the experimental group and the control group in terms of triglyceride, total cholesterol and urinary albumin excretion rate, and there was no statistical significance.After treatment, the urinary protein excretion rate and cholesterol and triglyceride levels in the experimental group were significantly lower than those in the control group, with statistical difference (P<0.05).In the control group of 25 patients, the total effective number of cases in the case of 20 cases, the effective rate was 80.0%.In the control group of 25 patients, the total effective number of cases in the case of 24 cases, the effective rate was 96.0%.As a result, the treatment effect of the patients in the control group was significantly lower than that in the experimental group, with statistical difference (P<0.05).There were no serious complications in diabetic nephropathy patients in the experimental group and the control group.ConclusionHuangkui capsule combined with valsartan in the treatment of diabetic nephropathy can improve the treatment efficiency to a great extent, high safety, no significant adverse reactions, improve the quality of life of patients, the maximum extent to reduce the pain of patients, with further clinical promotion and application significance.

diabetic nephropathyHuangkui capsulevalsartanclinical curative effect

吴仁凯、王杰、徐清喜

展开 >

象山县中医医院 中医内科,浙江 宁波 315700

糖尿病肾病 黄葵胶囊 缬沙坦 临床疗效

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.37(6)
  • 16
  • 7